Intravenous immunoglobulin and recurrent pregnancy loss
Intravenous immunoglobulin (IVIg) has been used to prevent pregnancy loss, in unexplained recurrent miscarriage, and in antiphospholipid syndrome (APS). When used on an unselected population with recurrent miscarriage, IVIg has not been shown to improve the live birth rate. However, when patients ar...
Gespeichert in:
| Veröffentlicht in: | Clinical Reviews in Allergy & Immunology 2005-12, Vol.29 (3), p.327-332 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 332 |
|---|---|
| container_issue | 3 |
| container_start_page | 327 |
| container_title | Clinical Reviews in Allergy & Immunology |
| container_volume | 29 |
| creator | Carp, Howard J A Sapir, Tal Shoenfeld, Yehuda |
| description | Intravenous immunoglobulin (IVIg) has been used to prevent pregnancy loss, in unexplained recurrent miscarriage, and in antiphospholipid syndrome (APS). When used on an unselected population with recurrent miscarriage, IVIg has not been shown to improve the live birth rate. However, when patients are selected for poor prognosis or autoimmune phenomena, IVIg has been shown to be effective. This article discusses the possible immune mechanisms by which IVIg may act and the effect of confounding factors such as embryonic chromosomal aberrations or anti-beta2-glycoprotein I antibodies in APS. Hence, there may be an impression of futility, when IVIg may be highly effective in saving those pregnancies that can be saved. Additionally, in an unselected population with recurrent miscarriage, there is a relatively good prognosis for a subsequent live birth (60%). Therefore, the spontaneous prognosis must be taken into account, which has not been the case in previous trials. |
| doi_str_mv | 10.1385/CRIAI:29:3:327 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69061843</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2410061161</sourcerecordid><originalsourceid>FETCH-LOGICAL-c266t-a9fbffd80c6129e46439ffff291a4315cbad085b39f6d225929336501c3acd553</originalsourceid><addsrcrecordid>eNqFkM1LxDAQxYMorq5ePUrx4K1rPpo0s7dl8aOwIIieQ5qmS5c2XZNW2P_e6C4oXpzLDMNvHvMeQlcEzwiT_G75UiyKOYU5mzOaH6EzgiVOMc_g-Nc8QechbDCmWDI4RRMiGJAMwxnKCzd4_WFdP4ak6brR9eu2L8e2cYl2VeKtGb23bki23q6ddmaXtH0IF-ik1m2wl4c-RW8P96_Lp3T1_FgsF6vUUCGGVENd1nUlsRGEgs1ExqCORYHojBFuSl1hycu4FRWlHCgwJjgmhmlTcc6m6Havu_X9-2jDoLomGNu22tn4shKABZEZ-xckIGQOGYngzR9w04_eRRMqAkJiKvIIzfaQ8dGst7Xa-qbTfqcIVl_Bq-_gFQXFVAw-HlwfVMeys9UPfkiafQLg7n2-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>879680267</pqid></control><display><type>article</type><title>Intravenous immunoglobulin and recurrent pregnancy loss</title><source>IngentaConnect</source><source>Open Access: PubMed Central</source><source>MEDLINE</source><source>Wiley Free Archive</source><source>Wiley</source><source>EZB Electronic Journals Library</source><source>SpringerLink Journals - AutoHoldings</source><creator>Carp, Howard J A ; Sapir, Tal ; Shoenfeld, Yehuda</creator><creatorcontrib>Carp, Howard J A ; Sapir, Tal ; Shoenfeld, Yehuda</creatorcontrib><description>Intravenous immunoglobulin (IVIg) has been used to prevent pregnancy loss, in unexplained recurrent miscarriage, and in antiphospholipid syndrome (APS). When used on an unselected population with recurrent miscarriage, IVIg has not been shown to improve the live birth rate. However, when patients are selected for poor prognosis or autoimmune phenomena, IVIg has been shown to be effective. This article discusses the possible immune mechanisms by which IVIg may act and the effect of confounding factors such as embryonic chromosomal aberrations or anti-beta2-glycoprotein I antibodies in APS. Hence, there may be an impression of futility, when IVIg may be highly effective in saving those pregnancies that can be saved. Additionally, in an unselected population with recurrent miscarriage, there is a relatively good prognosis for a subsequent live birth (60%). Therefore, the spontaneous prognosis must be taken into account, which has not been the case in previous trials.</description><identifier>ISSN: 1080-0549</identifier><identifier>EISSN: 1080-0549</identifier><identifier>EISSN: 1559-0267</identifier><identifier>EISSN: 1365-2567</identifier><identifier>DOI: 10.1385/CRIAI:29:3:327</identifier><identifier>PMID: 16391409</identifier><language>eng</language><publisher>United States: Springer Nature B.V</publisher><subject>Abortion, Habitual - drug therapy ; Abortion, Habitual - etiology ; Animals ; Antiphospholipid Syndrome - complications ; Antiphospholipid Syndrome - drug therapy ; Female ; Humans ; Immunoglobulins, Intravenous - therapeutic use ; Miscarriage ; Pregnancy</subject><ispartof>Clinical Reviews in Allergy & Immunology, 2005-12, Vol.29 (3), p.327-332</ispartof><rights>Humana Press Inc. 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c266t-a9fbffd80c6129e46439ffff291a4315cbad085b39f6d225929336501c3acd553</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16391409$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carp, Howard J A</creatorcontrib><creatorcontrib>Sapir, Tal</creatorcontrib><creatorcontrib>Shoenfeld, Yehuda</creatorcontrib><title>Intravenous immunoglobulin and recurrent pregnancy loss</title><title>Clinical Reviews in Allergy & Immunology</title><addtitle>Clin Rev Allergy Immunol</addtitle><description>Intravenous immunoglobulin (IVIg) has been used to prevent pregnancy loss, in unexplained recurrent miscarriage, and in antiphospholipid syndrome (APS). When used on an unselected population with recurrent miscarriage, IVIg has not been shown to improve the live birth rate. However, when patients are selected for poor prognosis or autoimmune phenomena, IVIg has been shown to be effective. This article discusses the possible immune mechanisms by which IVIg may act and the effect of confounding factors such as embryonic chromosomal aberrations or anti-beta2-glycoprotein I antibodies in APS. Hence, there may be an impression of futility, when IVIg may be highly effective in saving those pregnancies that can be saved. Additionally, in an unselected population with recurrent miscarriage, there is a relatively good prognosis for a subsequent live birth (60%). Therefore, the spontaneous prognosis must be taken into account, which has not been the case in previous trials.</description><subject>Abortion, Habitual - drug therapy</subject><subject>Abortion, Habitual - etiology</subject><subject>Animals</subject><subject>Antiphospholipid Syndrome - complications</subject><subject>Antiphospholipid Syndrome - drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Immunoglobulins, Intravenous - therapeutic use</subject><subject>Miscarriage</subject><subject>Pregnancy</subject><issn>1080-0549</issn><issn>1080-0549</issn><issn>1559-0267</issn><issn>1365-2567</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkM1LxDAQxYMorq5ePUrx4K1rPpo0s7dl8aOwIIieQ5qmS5c2XZNW2P_e6C4oXpzLDMNvHvMeQlcEzwiT_G75UiyKOYU5mzOaH6EzgiVOMc_g-Nc8QechbDCmWDI4RRMiGJAMwxnKCzd4_WFdP4ak6brR9eu2L8e2cYl2VeKtGb23bki23q6ddmaXtH0IF-ik1m2wl4c-RW8P96_Lp3T1_FgsF6vUUCGGVENd1nUlsRGEgs1ExqCORYHojBFuSl1hycu4FRWlHCgwJjgmhmlTcc6m6Havu_X9-2jDoLomGNu22tn4shKABZEZ-xckIGQOGYngzR9w04_eRRMqAkJiKvIIzfaQ8dGst7Xa-qbTfqcIVl_Bq-_gFQXFVAw-HlwfVMeys9UPfkiafQLg7n2-</recordid><startdate>200512</startdate><enddate>200512</enddate><creator>Carp, Howard J A</creator><creator>Sapir, Tal</creator><creator>Shoenfeld, Yehuda</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>200512</creationdate><title>Intravenous immunoglobulin and recurrent pregnancy loss</title><author>Carp, Howard J A ; Sapir, Tal ; Shoenfeld, Yehuda</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c266t-a9fbffd80c6129e46439ffff291a4315cbad085b39f6d225929336501c3acd553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Abortion, Habitual - drug therapy</topic><topic>Abortion, Habitual - etiology</topic><topic>Animals</topic><topic>Antiphospholipid Syndrome - complications</topic><topic>Antiphospholipid Syndrome - drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Immunoglobulins, Intravenous - therapeutic use</topic><topic>Miscarriage</topic><topic>Pregnancy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Carp, Howard J A</creatorcontrib><creatorcontrib>Sapir, Tal</creatorcontrib><creatorcontrib>Shoenfeld, Yehuda</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical Reviews in Allergy & Immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carp, Howard J A</au><au>Sapir, Tal</au><au>Shoenfeld, Yehuda</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intravenous immunoglobulin and recurrent pregnancy loss</atitle><jtitle>Clinical Reviews in Allergy & Immunology</jtitle><addtitle>Clin Rev Allergy Immunol</addtitle><date>2005-12</date><risdate>2005</risdate><volume>29</volume><issue>3</issue><spage>327</spage><epage>332</epage><pages>327-332</pages><issn>1080-0549</issn><eissn>1080-0549</eissn><eissn>1559-0267</eissn><eissn>1365-2567</eissn><abstract>Intravenous immunoglobulin (IVIg) has been used to prevent pregnancy loss, in unexplained recurrent miscarriage, and in antiphospholipid syndrome (APS). When used on an unselected population with recurrent miscarriage, IVIg has not been shown to improve the live birth rate. However, when patients are selected for poor prognosis or autoimmune phenomena, IVIg has been shown to be effective. This article discusses the possible immune mechanisms by which IVIg may act and the effect of confounding factors such as embryonic chromosomal aberrations or anti-beta2-glycoprotein I antibodies in APS. Hence, there may be an impression of futility, when IVIg may be highly effective in saving those pregnancies that can be saved. Additionally, in an unselected population with recurrent miscarriage, there is a relatively good prognosis for a subsequent live birth (60%). Therefore, the spontaneous prognosis must be taken into account, which has not been the case in previous trials.</abstract><cop>United States</cop><pub>Springer Nature B.V</pub><pmid>16391409</pmid><doi>10.1385/CRIAI:29:3:327</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1080-0549 |
| ispartof | Clinical Reviews in Allergy & Immunology, 2005-12, Vol.29 (3), p.327-332 |
| issn | 1080-0549 1080-0549 1559-0267 1365-2567 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69061843 |
| source | IngentaConnect; Open Access: PubMed Central; MEDLINE; Wiley Free Archive; Wiley; EZB Electronic Journals Library; SpringerLink Journals - AutoHoldings |
| subjects | Abortion, Habitual - drug therapy Abortion, Habitual - etiology Animals Antiphospholipid Syndrome - complications Antiphospholipid Syndrome - drug therapy Female Humans Immunoglobulins, Intravenous - therapeutic use Miscarriage Pregnancy |
| title | Intravenous immunoglobulin and recurrent pregnancy loss |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T18%3A21%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intravenous%20immunoglobulin%20and%20recurrent%20pregnancy%20loss&rft.jtitle=Clinical%20Reviews%20in%20Allergy%20&%20Immunology&rft.au=Carp,%20Howard%20J%20A&rft.date=2005-12&rft.volume=29&rft.issue=3&rft.spage=327&rft.epage=332&rft.pages=327-332&rft.issn=1080-0549&rft.eissn=1080-0549&rft_id=info:doi/10.1385/CRIAI:29:3:327&rft_dat=%3Cproquest_cross%3E2410061161%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=879680267&rft_id=info:pmid/16391409&rfr_iscdi=true |